These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 10412541)

  • 1. [New dopaminergic agonists].
    de Mattos JP; Mattos VM
    Arq Neuropsiquiatr; 1999 Jun; 57(2A):329-32. PubMed ID: 10412541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dopaminergic agonists in the treatment of Parkinson's disease].
    Supiot F; Sternon J; Zegers de Beyl D
    Rev Med Brux; 2000 Dec; 21(6):493-9. PubMed ID: 11194495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
    Rascol O; Lees AJ; Senard JM; Pirtosek Z; Brefel C; Montastruc JL; Fuell D
    Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term studies of dopamine agonists.
    Hubble JP
    Neurology; 2002 Feb; 58(4 Suppl 1):S42-50. PubMed ID: 11909984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
    Etminan M; Samii A; Takkouche B; Rochon PA
    Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agonists versus levodopa in PD: the thrilla of whitha.
    Montgomery EB
    Neurology; 2003 Nov; 61(10):1462; author reply 1462-3. PubMed ID: 14638991
    [No Abstract]   [Full Text] [Related]  

  • 10. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
    Jenner P
    Neurology; 2004 Jan; 62(1 Suppl 1):S47-55. PubMed ID: 14718680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine agonists.
    Tuite P; Ebbitt B
    Semin Neurol; 2001; 21(1):9-14. PubMed ID: 11346030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramipexole, ropinirole, and mania in Parkinson's disease.
    Singh A; Althoff R; Martineau RJ; Jacobson J
    Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa.
    Marek K; Jennings D; Seibyl J
    Neurology; 2003 Sep; 61(6 Suppl 3):S43-8. PubMed ID: 14504379
    [No Abstract]   [Full Text] [Related]  

  • 16. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic agonists in Parkinson's disease.
    Alonso Cánovas A; Luquin Piudo R; García Ruiz-Espiga P; Burguera JA; Campos Arillo V; Castro A; Linazasoro G; López Del Val J; Vela L; Martínez Castrillo JC
    Neurologia; 2014 May; 29(4):230-41. PubMed ID: 21724302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of two different dopamine agonists in the management of Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
    Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An approach to the continuous dopaminergic stimulation in Parkinson's disease.
    Schwartz M; Sabetay S
    Isr Med Assoc J; 2012 Mar; 14(3):175-9. PubMed ID: 22675859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical treatment of later-stage motor problems of Parkinson disease.
    Ahlskog JE
    Mayo Clin Proc; 1999 Dec; 74(12):1239-54. PubMed ID: 10593354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.